Repare Therapeutics 주식 (NASDAQ: RPTX)

Repare Therapeutics (NASDAQ:RPTX) 주식

Repare Therapeutics

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

Cathie Wood Smelling AI Opportunity? Ark Invest Buys Tempus AI Dip, Scoops Up Over $13 M Worth Of Stock

Equities

News

Markets

ETFs

ARKF

ARKG

ARKK

ARKW

CDNA

GTLB

IBTA

NTLA

PATH

PRME

RBLX

RPTX

2025년 3월 14일 금요일, 캐시 우드가 이끄는 아크 인베스트가 깃랩(NASDAQ:GTLB), 인텔리아 테라퓨틱스(NGM:NTLA), 프라임 메디슨(NGM:PRME), 유아이패스(NYSE:PATH), 아이보타(NYSE:IBTA), 로블록스(NYSE:RBLX), 리페어 테라퓨틱스(NASDAQ:RPTX) 및 케어DX(NASDAQ:CDNA)에 대해 큰 매매를 했다.

아크 인베스트: 유아이패스와 로블록스 주식을 계속 처분, 깃랩과 아이보타를 매수

Repare Therapeutics Inc

Truist Securities analyst Michael Lewis maintains Sila Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SILA#NYSE">SILA</a>) with a Buy and raises the price target from $27 to $28.

Price Target

Analyst Ratings

SILA

Truist Securities Maintains Buy on Sila Realty Trust, Raises Price Target to $28

U.S. retail sales showed a rebound in February following a sharp decline in January, yet the pace of the broader recovery fell short of economists&#8217; expectations, underscoring some challenges facing the American economy <a href="https://www.benzinga.com/news/econ-s">in the first quarter.</a>
Retail sales rose 0.2% month-over-month in February 2025, following a downwardly revised 1.2% contraction in January, according to advance estimates from the U.S. Census Bureau released Monday. The figure missed economist projections of a 0.6% increase, as tracked by TradingEconomics.
On an annual basis, retail sales grew 3.1%, slowing from the previous downwardly revised 3.9% growth.
Yet, key data in the report revealed underlying strength across major consumer categories. 
Non-store retailers, a key gauge of online sales, rose by 2.4% month-over-month and health and personal care stores soared by 1.7%. 
Excluding gas stations and auto sales, retail sales rose 0.5% month-over-month, rebounding from January&#8217;s 0.8% decline and outperforming expectations of a 0.4% gain.
The control group measure—which excludes sales from auto dealers, building materials, gas stations, office supply stores, mobile home dealers, and tobacco retailers—climbed 1% in February, fully offsetting January's 1% drop and vastly outperforming the expected 0.2% increase.
<h3 class="wp-block-heading">Market Reaction</h3>
U.S. stock futures rebounded following the retail trade report. As of 8:40 a.m. Eastern Time, S&amp;P 500 futures were down 0.1%, trimming earlier losses.. 
On Friday, the S&amp;P 500—tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)—closed 2.1% higher but still logged its fourth consecutive weekly loss.
Meanwhile, gold futures were up 0.3% extending their rally, after having closed their 10th positive week out of the last 11.
The U.S. dollar Index – a key measure of the greenback's strength – was down 0.1%.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/tech/25/03/44352209/gtc-2025-could-reignite-nvidias-stock-rally-but-only-if-b300-ai-server-roadmap-and-scaling-concerns-are-addressed-says-top-analyst">GTC 2025 Could Reignite Nvidia&#8217;s Stock Rally, But Only If B300, AI Server Roadmap, And Scaling Concerns Are Addressed, Says Top Analyst</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

Retail Sales Rebound Less Than Expected In February: Online, Healthcare Spending Show Strong Gains

Truist Securities analyst Richard Newitter maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Buy and lowers the price target from $666 to $605.

ISRG

Truist Securities Maintains Buy on Intuitive Surgical, Lowers Price Target to $605

Harte-Hanks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HHS#NASDAQ">HHS</a>) reported quarterly losses of $(0.33) per share. This is a 22.22 percent decrease over losses of $(0.27) per share from the same period last year. The company reported $47.13 million in sales this quarter. This is a 4.77 percent decrease over sales of $49.49 million the same period last year.

Earnings

Harte-Hanks Q4 EPS $(0.33) Down From $(0.27) YoY, Sales $47.13M Down From $49.49M YoY

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) is a &#8220;meme&#8221; stock and that he doesn't need it because it&#8217;s losing <a href="https://www.benzinga.com/quote/SERV/earnings">too much money</a>.
The company reported weaker-than-expected fourth-quarter results. Adjusted EPS loss of 23 cents missed the consensus estimate for a loss of 18 cents.
&#8220;I'm kind of blown away about how badly the stock acts,&#8221; Cramer said when asked about The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>). &#8220;We get them on, maybe we can get some answers. Otherwise it's going to keep going down I'm afraid. &#8220;
As per the recent news, Trade Desk announced the appointment of Vivek Kundra as CEO, effective March 31.
Jim Cramer recommended buying Louisiana-Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>) here.
On Feb. 19, Louisiana-Pacific reported fourth-quarter net sales growth of 3.5% year-over-year to $681 million, beating the consensus of $666.753 million.
Cramer said Enbridge Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) has &#8220;got so much business in America&#8221; and added that it's a great idea to buy the stock.
In the recent news, Enbridge named Steven W. Williams as chair of the board, effective May 7.
SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) is a &#8220;meme&#8221; stock, Cramer said.
The company announced it will participate in the 2025 Nvidia GPU Technology Conference.
The Mad Money host recommended buying Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>).
Accenture on Thursday announced a strategic investment in OPAQUE, a firm providing a secure AI platform designed to allow organizations to run large-scale, general-purpose AI workloads with encrypted data.
Price Action:
<ul>
<li>Serve Robotics shares jumped 9.1% to settle at $7.66 on Friday.</li>
<li>Trade Desk shares rose 0.1% to close at $53.94 during the session.</li>
<li>Louisiana-Pacific shares gained 2.4% to settle at $91.55.</li>
<li>Enbridge shares rose 0.7% to close at $42.83.</li>
<li>SoundHound AI shares jumped 16.1% to close at $10.34 on Friday.</li>
<li>Accenture shares gained 0.6% to settle at $318.82.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44326690/top-3-materials-stocks-that-may-collapse-in-march">Top 3 Materials Stocks That May Collapse In March</a></li>
</ul>
Photo: Shutterstock

Media

Trading Ideas

SERV

SOUN

Jim Cramer Calls This Stock A 'Meme Stock,' Recommends Buying Accenture

Truist Securities analyst Jake Bartlett maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Buy and raises the price target from $200 to $212.

Truist Securities Maintains Buy on Darden Restaurants, Raises Price Target to $212

WIIM

ANTE

AirNet Technology shares are trading higher after the company announced the execution of a non-binding investment LOI with LLP STH Corp, a Kazakstan company.

Intel Corp&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) incoming CEO, Lip-Bu Tan, is planning a major overhaul of the company&#8217;s chip manufacturing and artificial intelligence operations, aiming to breathe new life into the struggling tech giant.
What Happened: Tan is considering significant changes to the company&#8217;s approach to AI and chip manufacturing. This includes staff cuts to address what he sees as a slow-moving and bloated middle management layer, according to a Reuters report on Monday.
Revamping the manufacturing operations, which once exclusively produced chips, but now also cater to external clients like Nvidia, is one of Tan&#8217;s key priorities.
Tan, who was previously a member of Intel&#8217;s board and&nbsp;CEO of chip design software&nbsp;firm Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) is poised to lead the company after a decade of setbacks under previous CEOs. These missteps led to Intel missing out on the booming demand for AI processors and smartphone chips, allowing competitors like Arm Holdings and Nvidia to dominate these markets.
Under Tan&#8217;s leadership, Intel is striving to enhance the performance of its manufacturing division, Intel Foundry, by actively securing new customers. The company also plans to restart the production of&nbsp;chips that drive AI servers&nbsp;and explore areas beyond servers, such as software, robotics, and AI foundation models.
SEE ALSO: <a href="https://www.benzinga.com/tech/25/03/44296708/ibm-ceo-arvind-krishna-says-deepseek-an-indicator-of-whats-to-come-predicts-ai-models-will-use-just-1-of-todays-energy-in-5-years">IBM CEO Arvind Krishna Says DeepSeek An Indicator Of What&#8217;s To Come, Predicts AI Models Will Use Just 1% Of Today&#8217;s Energy In 5 Years</a>
Why It Matters: Despite the ambitious plans, Tan&#8217;s strategy seems to be an enhancement of former CEO Pat Gelsinger&#8216;s turnaround plan, which sought to reshape Intel into a contract chip manufacturer. However, Gelsinger&#8217;s plan had to be scaled back due to cooling demand for Intel&#8217;s core products.
Tan&#8217;s appointment as CEO was announced on March 13, and it led to a surge in <a href="https://www.benzinga.com/markets/25/03/44297910/intel-stock-soars-nearly-12-in-thursday-pre-market-whats-going-on">Intel&#8217;s stock</a>. His incoming leadership and the proposed changes are seen as a potential turning point for Intel, which has been struggling to keep up with competitors in the rapidly evolving tech industry. In a town hall address held after his appointment, the CEO cautioned employees that the company will need to make &#8220;tough decisions.&#8221;
As Tan steps into his new role, the tech industry will be watching closely to see if his planned changes can turn around the fortunes of the ailing tech giant.
Intel stock has surged more than 18% over the past 5 days to close at $24.05 on Friday, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Intel holds a momentum rating of 31.37% and a growth rating of 80.60%, according to&nbsp;<a href="https://www.benzinga.com/report/INTC" target="_blank" rel="noreferrer noopener">Benzinga's Proprietary Edge Rankings</a>. The Benzinga Growth metric evaluates a stock&#8217;s historical earnings and revenue expansion across multiple timeframes, prioritizing both long-term trends and recent performance. For an in-depth report on more stocks and insights into growth opportunities,&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">sign</a>&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">up for Benzinga Edge.</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="445" height="281" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17082207/image-139.png" alt="" class="wp-image-827199" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17082207/image-139.png 445w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17082207/image-139-300x189.png 300w" sizes="(max-width: 445px) 100vw, 445px" /></figure>
READ MORE:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44352234/astrazeneca-seals-deal-for-esobiotec-to-advance-cell-therapy-details">AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

CDNS

INTC

Intel's New CEO Charts Revival Plan, Warns Of 'Tough Decisions' Ahead: Report

UBS analyst Brennan Hawken upgrades Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) from Neutral to Buy and maintains the price target from $180 to $180.

Upgrades

UBS Upgrades Blackstone to Buy, Maintains Price Target to $180

Truist Securities analyst Bertrand Donnes maintains BKV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKV#NYSE">BKV</a>) with a Buy and lowers the price target from $31 to $30.

Truist Securities Maintains Buy on BKV, Lowers Price Target to $30

Castellum shares are trading lower after the company announced the pricing of a $4.5 million public offering of common stock and warrants.

<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17074527/WechatIMG18690-1024x576.png" alt="" class="wp-image-8014" style="width:928px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17074527/WechatIMG18690-1024x576.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17074527/WechatIMG18690-300x169.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17074527/WechatIMG18690-768x432.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17074527/WechatIMG18690.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The car trader that recently shifted to bitcoin mining said a group wants to buy a controlling stake from Cango's co-founders
Cango Inc.&nbsp;(CANG.US)&nbsp;<a href="https://www.prnewswire.com/news-releases/cango-inc-announces-receipt-of-a-preliminary-non-binding-letter-of-intent-and-formation-of-special-committee-302401855.html#:~:text=(NYSE%3A%20CANG)%20(%22,its%20non%2Dbinding%20intent%20to">said on Friday</a>&nbsp;it has been approached by an investor interested in taking control of the company, representing the first such bid since its pivot late last year from car trading services to bitcoin mining. Such offers typically carry big premiums to a company's current value, which for Cango currently stands at about $400 million.
Cango said it received the non-binding letter of intent to obtain control of the company from Enduring Wealth Capital Ltd., which wants to acquire 10 million Class-B shares held by Cango co-founders Zhang Xiaojun and Lin Jiayuan. Zhang is currently Cango's chairman, while Lin is its CEO. Zhang held 22.8% of Cango's ordinary shares with 48.4% of its voting power at the end of 2023, while Lin held 22.4% with 44.1% of the voting power, according to the company's latest annual report filed last April.
Enduring Wealth said it would like to purchase the 10 million shares from the co-founders "at a purchase price in cash to be agreed among the parties," according to Cango. As part of any agreement, Cango's management would be "restructured in such manner as requested by Enduring Wealth Capital," the statement added.
Furthermore, any deal would likely require Cango to dispose of its existing car-trading business in China, with Enduring Wealth offering to "introduce a potential buyer." Such moves would allow Cango, which is based in China but operates its bitcoin mining business outside the country, to terminate its status as a "China concept stock" with the U.S. securities regulator.
Enduring Capital's key decision makers are Andrea Dal Mas and Yu Peng, who are both directors of the company. Dal Mas' LinkedIn profile describes him as a managing partner at Singapore-based Antalpha Ventures, "where he focuses on strategic investments in blockchain technology and artificial intelligence companies." Cango described Yu as "a seasoned and accomplished finance professional with extensive experience in investment management and asset management." Yu was described as Antalpha's chief strategy officer in an August 2024 announcement from virtual asset manager Pando.
Cango said its board resolved to form a committee consisting of its three independent directors to consider the proposal.
Cango's shares rose 14.6% in Friday trading after the announcement. The company's stock is up nearly 150% over the last six months, most of that coming after Cango announced its entry into the bitcoin mining business last November. Before that, the company was mostly focused on the car business in China, starting as an auto financer before more recently shifting its business to auto trading services.
Cango used its large cash reserves to enter the bitcoin mining business, purchasing $250 million worth of mining machines with plans to acquire another $150 million worth. The company began mining bitcoins in November and had mined 1,944.2 bitcoins through the end of February.
Following its entry to the bitcoin mining business, the company's revenue jumped by more than a factor of five to 668 million yuan ($92 million) in last year's fourth quarter from 130.2 million a year earlier. Most of that came from the new bitcoin mining business, though the company continues to operate its car-trading business that offers both domestic and transborder trading services.

Signals

CANG

Cango Stock Rises ~15% On Buyout Interest

Truist Securities analyst Neal Dingmann maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Buy and lowers the price target from $133 to $131.

Truist Securities Maintains Buy on Expand Energy, Lowers Price Target to $131

UBS analyst Manav Gupta upgrades Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) from Sell to Neutral and lowers the price target from $15 to $12.

CLMT

UBS Upgrades Calumet to Neutral, Lowers Price Target to $12

Truist Securities analyst Bertrand Hodee maintains Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Hold and raises the price target from $35 to $37.

Truist Securities Maintains Hold on Range Resources, Raises Price Target to $37

Citigroup analyst Andrew Kaplowitz reinstates Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Buy and announces $132 price target.

Initiation

Citigroup Reinstates Buy on Emerson Electric, Announces $132 Price Target

Science Applications International Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading higher in premarket</a> on Monday after the fourth-quarter FY25 earnings.
The company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44352871/saic-announces-fourth-quarter-and-full-fiscal-year-2025-results" rel="noreferrer noopener">fourth-quarter sales growth </a>of 6% year-on-year to $1.84 billion, beating the analyst consensus estimate of $1.81 billion.
Adjusted EPS of $2.57 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the consensus </a>estimate of $2.08.
The operating income for the quarter jumped 75% to $138 million and the operating margin expanded by 300 basis points to 7.5%.
Adjusted EBITDA increased 39% to $177 million with an adjusted EBITDA margin of 9.6%, a 230 basis points expansion.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44352234/astrazeneca-seals-deal-for-esobiotec-to-advance-cell-therapy-details" rel="noreferrer noopener">AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details</a>
Net bookings for the quarter were approximately $1.3 billion, which reflects a book-to-bill ratio of approximately 0.7.  The operating cash flow for the quarter totaled $115 million, with transaction-adjusted free cash flow of $236 million.
SAIC&#8217;s estimated backlog at the end of fiscal year 2025 was approximately $21.9 billion of which $3.4 billion was funded. The company held $64 million in cash and equivalents as of January 31, 2025.
&#8220;Subsequent to quarter close, we received a $1.8 billion award for our largest recompete win in recent years, the System Software Lifecycle Engineering program. This important win along with&nbsp;a backlog of submitted bids valued at approximately $20 billion reflect the momentum we are building inside the company,&#8221; said CEO Toni Townes-Whitley.
Outlook: Science Applications revised the FY26 revenue outlook from $7.55 billion &#8211; $7.75 billion to $7.60 billion &#8211; $7.75 billion versus an estimate of $7.644 billion.
The company also raised the FY26 adjusted EPS outlook from $8.90 &#8211; $9.10 to $9.10 &#8211; $9.30 against an estimate of $9.07.
Price Action: SAIC shares traded higher by 9.16% at $114.00 in premarket at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44327146/whats-going-on-with-palantir-technologies-stock-today" target="_blank" rel="noreferrer noopener">Palantir Technologies Partners With RCM Company R1For AI Lab</a></li>
</ul>

Guidance

Movers

General

SAIC

Science Applications Q4 Earnings Crush Estimates Helped By New Contract Volume, Stock Gains

Citigroup analyst Lydia Ling downgrades RLX Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) from Buy to Neutral and lowers the price target from $2.8 to $2.5.

Downgrades

Citigroup Downgrades RLX Technology to Neutral, Lowers Price Target to $2.5

Earnings Beats

SBET

SharpLink Gaming FY24 EPS $2.29 Up From $(5.19) YoY; Revenue $3.662M Down From $4.952M YoY

Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) ("Guess?" or the "Company") today announced that its Board of Directors (the "Board") has received a non-binding proposal from WHP Global through its affiliate WHP Investments, LLC, to acquire for $13.00 per share in cash the outstanding shares of Guess?, Inc., other than shares held by certain existing shareholders, including Paul Marciano, Maurice Marciano and Carlos Alberini (collectively, the "Proposed Rollover Shareholders"). The proposal contemplates that the proposed transaction would be financed through a combination of equity and third-party debt financing, as well as rollover or reinvestment by each of the Proposed Rollover Shareholders, and assumes that the Company will operate in the ordinary course of business and that there will be no material change to the strategic and operational position of the Company.
Guess? has formed a Special Committee of independent and disinterested directors of the Board (the "Special Committee") to evaluate the proposal, with the assistance of outside financial and legal advisors, to determine the course of action that is in the best interest of Guess? and its shareholders.
There is no guarantee that any definitive offer will be made, that any agreement will be executed or that the proposed transaction in the proposal or any other transaction will be approved or completed. Guess? does not intend to comment further on this matter until the Special Committee has completed its evaluation of the proposal or until further disclosure is deemed appropriate. Guess? shareholders do not need to take any action at this time.
In April 2024, the Company partnered with WHP Global to acquire the intellectual property and operating assets of New York-based fashion brand rag &amp; bone, a leader in the American fashion scene, with the Company directly operating rag &amp; bone stores in the U.S. and in the U.K., and also having rag &amp; bone available in high-end boutiques, department stores and through e-commerce globally.

Guess? Receives Non-Binding Going-Private Proposal From WHP Global; To Acquire The Company For  $13.00 Per Share In Cash

Press Releases

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Opinion

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Comments

Repare Therapeutics

뉴스

파트너 / 기고자

벤징가 글로벌